Publications

@article{Gansane2021-yh,

title = {Anti-malarial efficacy and resistance monitoring of  artemether-lumefantrine and dihydroartemisinin-piperaquine shows  inadequate efficacy in children in Burkina Faso, 2017-2018},

author = {Adama Gansan\'{e} and Leah F Moriarty and Didier M\'{e}nard and Isidore Yerbanga and Esperance Ouedraogo and Paul Sondo and Rene Kinda and Casimir Tarama and Edwige Soulama and Madou Tapsoba and David Kangoye and Cheick Said Compaore and Ousmane Badolo and Blami Dao and Samuel Tchwenko and Halidou Tinto and Innocent Valea},

doi = {10.1186/s12936-021-03585-6},

issn = {1475-2875},

year  = {2021},

date = {2021-01-19},

urldate = {2021-01-01},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {48},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: The World Health Organization recommends regularly 

 assessing the efficacy of artemisinin-based combination therapy 

 (ACT), which is a critical tool in the fight against malaria. 

 This study evaluated the efficacy of two artemisinin-based 

 combinations recommended to treat uncomplicated Plasmodium 

 falciparum malaria in Burkina Faso in three sites: Niangoloko, 

 Nanoro, and Gourcy. METHODS: This was a two-arm randomized 

 control trial of the efficacy of artemether-lumefantrine (AL) 

 and dihydroartemisinin-piperaquine (DP). Children aged 6-59 

 months old were monitored for 42 days. The primary outcomes of 

 the study were uncorrected and PCR-corrected efficacies to day 

 28 for AL and 42 for DP. Molecular markers of resistance to 

 artemisinin derivatives and partner drugs were also analysed. 

 RESULTS: Of 720 children enrolled, 672 reached study endpoints 

 at day 28, 333 in the AL arm and 339 in the DP arm. 

 PCR-corrected 28-day per protocol efficacy in the AL arm was 

 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% 

 (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol 

 efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% 

 (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 

 mutation previously associated with artemisinin-resistance was 

 observed. No statistically significant association was found 

 between treatment outcome and presence of the 86Y mutation in 

 the Pfmdr1 gene. There was also no association observed between 

 treatment outcome and Pfpm2 or Pfmdr1 copy number variation. 

 CONCLUSION: The results of this study indicate evidence of 

 inadequate efficacy of AL at day 28 and DP at day 42 in the same 

 two sites. A change of first-line ACT may be warranted in 

 Burkina Faso. Trial Registry Pan African Clinical Trial Registry 

 Identifier: PACTR201708002499311. Date of registration: 8/3/2017 

 https://pactr.samrc.ac.za/Search.aspx.},

keywords = {Antimalarial, Antimalarials/pharmacology, Artemether, Artemether-lumefantrine, Artemisinins/pharmacology, Burkina Faso, Child, Dihydroartemisinin-piperaquine, Drug Resistance, Efficacy, Falciparum/drug therapy, Female, Lumefantrine Drug Combination/pharmacology, Malaria, Male, Plasmodium falciparum, Preschool, Quinolines/pharmacology},

pubstate = {published},

tppubtype = {article}

}

@article{Adjuik2015,

title = {The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: A meta-analysis of individual patient data},

author = {Martin A. Adjuik and Richard Allan and Anupkumar R. Anvikar and Elizabeth A. Ashley and Mamadou S. Ba and Hubert Barennes and Karen I. Barnes and Quique Bassat and Elisabeth Baudin and Anders Bj\"{o}rkman and Fran\c{c}ois Bompart and Maryline Bonnet and Steffen Borrmann and Philippe Brasseur and Hasifa Bukirwa and Francesco Checchi and Michel Cot and Prabin Dahal and Umberto D'Alessandro and Philippe Deloron and Meghna Desai and Graciela Diap and Abdoulaye A. Djimde and Grant Dorsey and Ogobara K. Doumbo and Emmanuelle Espi\'{e} and Jean Francois Etard and Caterina I. Fanello and Jean Fran\c{c}ois Faucher and Babacar Faye and Jennifer A. Flegg and Oumar Gaye and Peter W. Gething and Raquel Gonz\'{a}lez and Francesco Grandesso and Philippe J. Guerin and Jean Paul Guthmann and Sally Hamour and Armedy Ronny Hasugian and Simon I. Hay and Georgina S. Humphreys and Vincent Jullien and Elizabeth Juma and Moses R. Kamya and Corine Karema and Jean R. Kiechel and Peter G. Kremsner and Sanjeev Krishna and Val\'{e}rie Lameyre and Laminou M. Ibrahim and Sue J. Lee and Bertrand Lell and Andreas Martensson and Achille Massougbodji and Herv\'{e} Menan and Didier M\'{e}nard and Clara Men\'{e}ndez and Martin Meremikwu and Clarissa Moreira and Carolyn Nabasumba and Michael Nambozi and Jean Louis Ndiaye and Frederic Nikiema and Christian Nsanzabana and Francine Ntoumi and Bernhards R. Ogutu and Piero Olliaro and Lyda Osorio and Jean Bosco Ou\'{e}draogo and Louis K. Penali and Mbaye Pene and Loretxu Pinoges and Patrice Piola and Ric N. Price and Cally Roper and Philip J. Rosenthal and Claude Emile Rwagacondo and Albert Same-Ekobo and Birgit Schramm and Amadou Seck and Bhawna Sharma and Carol Hopkins Sibley and V\'{e}ronique Sinou and Sodiomon B. Sirima and Jeffery J. Smith and Frank Smithuis and Fabrice A. Som\'{e} and Doudou Sow and Sarah G. Staedke and Kasia Stepniewska and Todd D. Swarthout and Khadime Sylla and Ambrose O. Talisuna and Joel Tarning and Walter R. J. Taylor and Emmanuel A. Temu and Julie I. Thwing and Emiliana Tjitra and Roger C. K. Tine and Halidou Tinto and Michel T. Vaillant and Neena Valecha and Ingrid Van Broek and Nicholas J. White and Adoke Yeka and Issaka Zongo},

doi = {10.1186/s12916-015-0301-z},

issn = {17417015},

year  = {2015},

date = {2015-01-01},

journal = {BMC Medicine},

volume = {13},

issue = {1},

publisher = {BioMed Central Ltd.},

abstract = {Background: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria. Methods: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites. Results: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P \< 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated with a 3.5-fold greater risk of recrudescence by day 28 (adjusted hazard ratio},

keywords = {Amodiaquine, Artesunate, Dosing, Drug Resistance, Efficacy, Malaria, Plasmodium falciparum},

pubstate = {published},

tppubtype = {article}

}